NovaDel Announces Two CNS Oral Spray Drug Candidates in its Development Pipeline
Press Release Source: NovaDel Pharma Inc.
Wednesday September 13, 9:05 am ET
Oral Spray Formulations of Tizanidine for Spasticity and Ropinirole for Parkinson's Disease
FLEMINGTON, N.J.--(BUSINESS WIRE)--Sept. 13, 2006--NovaDel Pharma (AMEX: NVD - News) today announced the two latest additions to its pipeline of oral spray drug development candidates. NovaDel's new programs are focused on treating disorders of the central nervous system (CNS), with Tizanidine Oral Spray (formerly NVD 422) for spasticity and Ropinirole Oral Spray (formerly NVD 434) for Parkinson's disease
. NovaDel has completed development of the new oral formulations for both compounds and is currently finalizing the preclinical characterization of these oral sprays.
"NovaDel's oral spray technology may be particularly applicable to drugs for the treatment of CNS disorders where the oral sprays ability to overcome difficulty in swallowing tablets and achieving rapid onset of action could fulfill important unmet medical needs for patients," commented Jan Egberts, M.D., CEO of NovaDel. "For instance, we expect that the ease of administering Tizanidine Oral Spray will be well suited to patients suffering from spasticity, which often includes difficulty in swallowing and drugs administered via tablet represent an obstacle to treatment.
"NovaDel's newest development candidates share several benefits common to all of the drug candidates in our pipeline," continued Egberts. "These drug candidates have ease of administration associated with oral spray that may provide substantial benefits compared with the current modes of administration and they may have improved pharmacokinetics enabling more rapid relief. Importantly, NovaDel expects both tizanidine and ropinirole oral sprays to enter clinical trials in the first quarter of 2007 and progress through the shortened 505(b)(2) regulatory process."
About Tizanidine Oral Spray
Spasticity is a symptom of several neurological disorders, including multiple sclerosis, spinal cord injury, stroke and cerebral palsy, and leads to involuntary tensing, stiffening and contracting of muscles. Tizanidine treats spasticity by blocking nerve impulses through pre-synaptic inhibition of motor neurons. This method of action results in decreased spasticity without a corresponding reduction in muscle strength. Because patients experiencing spasticity may have difficulty swallowing the tablet formulation of the drug, NovaDel's Tizanidine Oral Spray may provide patients suffering from spasticity with a very convenient solution to this serious treatment problem.
Spasticity affects over 500,000 people in the U.S. alone. Spasticity is not a disease, but rather a symptom of various neurological disorders, including, but not limited to, multiple sclerosis (MS), spinal cord injury (SCI), stroke and cerebral palsy. These disorders cause a change in the balance of signals between the central nervous system and the muscles. This imbalance leads to involuntary tensing, stiffening and contracting of muscles. Tizanidine is the most widely prescribed treatment for spasticity with approximately four million prescriptions written annually.
About Ropinirole Oral Spray
Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Ropinirole Oral Spray is ideal for the geriatric population who may be suffering from dysphagia (difficulty swallowing) and 85% of suffers of Parkinson's are 65 years of age or older and 45% of elderly people have some difficulty in swallowing. NovaDel's formulation of Ropinirole Oral Spray may represent a more convenient way for the patient or healthcare provider to deliver ropinirole to patients suffering stiffness and/or tremors. Ropinirole is currently marketed by GlaxoSmithKline as Requip® and had sales of $160 million in 2005.